Published in Medical Verdicts and Law Weekly, March 9th, 2006
ACT's operation of a laboratory capable of manufacturing clinical-grade product based on human embryonic stem cell technology part of the company's commitment to developing new human therapies in the emerging field of regenerative medicine. In conjunction with the sublease, the company acquired cell culture and manufacturing equipment previously validated for use in the GMP manufacture of cell-based therapies.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.